XBI Stock Recent News

XBI LATEST HEADLINES

XBI Stock News Image - nypost.com

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.

nypost.com 2025 Mar 31
XBI Stock News Image - youtube.com

Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.

youtube.com 2025 Mar 05
XBI Stock News Image - zacks.com

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

zacks.com 2025 Mar 05
XBI Stock News Image - seekingalpha.com

Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides more leverage to the biotech turnaround trade. Falling interest rates, weak GDP growth, low inflation, and Fed rate cuts mean the macro environment is ripe for biotech.

seekingalpha.com 2025 Mar 02
XBI Stock News Image - globenewswire.com

Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months

globenewswire.com 2025 Feb 07
XBI Stock News Image - etftrends.com

The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.

etftrends.com 2025 Feb 03
XBI Stock News Image - zacks.com

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

zacks.com 2025 Feb 03
XBI Stock News Image - seekingalpha.com

SPDR® S&P Biotech ETF is a strong investment due to rising demand for biotech solutions addressing chronic diseases and its diverse, equal-weighted portfolio. XBI's equal-weighting strategy reduces concentration risk and balances risk-reward by investing in large, mid, and small-cap biotech companies. Strong industry trends and government support, including increasing NIH funding, bolster XBI's long-term growth potential despite short-term volatility from RFK's appointment.

seekingalpha.com 2025 Jan 30
XBI Stock News Image - seekingalpha.com

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.

seekingalpha.com 2025 Jan 22
XBI Stock News Image - seekingalpha.com

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.

seekingalpha.com 2025 Jan 13
10 of 50